Last updated 5 months ago

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

357 patients around the world
Available in United States, Brazil, Spain
GlaxoSmithKline
357Patients around the world

This study is for people with

Multiple myeloma

Requirements for the patient

From 18 Years
All Gender

Medical requirements

LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy